Timothy Craig Allen, MD, JD, FCAP
Articles by Timothy Craig Allen, MD, JD, FCAP
Novel HER2-Targeted Therapies for NSCLC
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Closing out their discussion, the panel highlights investigational therapies in NSCLC to look out for.
Challenges and Unmet Needs in HER2-Mutated or Amplified NSCLC
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS The panel discusses the challenges of treatment and unmet needs of HER2-mutated or amplified NSCLC.
Unmet Needs in NSCLC Therapy
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Drs Anil Vachani and Mark Socinski continue their discussion of anti-HER2 therapies by mentioning some of the unmet needs in NSCLC treatment despite the range of available treatment options.
Major Adverse Events of Anti-HER2 Therapies
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Drs Socinski and Vachani explain the typical adverse events seen with anti-HER2 therapies and how to manage them.
HER2-Targeted Therapies in NSCLC
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Drs Timothy Craig Allen and Ticiana Leal review the HER2-targeted therapies in NSCLC, including mechanism of action and supportive clinical trial data.
Clinical Scenario: A 72-Year-Old Man with HER2-Amplified NSCLC
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Solange Peters, MD, PhD, presents the case of a 72-year-old man with HER2-amplified NSCLC and starts a discussion on the recommended treatment plans.
Current Treatment Options in NSCLC
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Dr Mark A Socinski reviews the currently available treatment options for NSCLC, including targeted therapies.
Testing Patients with NSCLC for HER2 Mutations
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Anil Vachani, MD, MS, explains whether he orders biomarker testing for all patients with HER2-mutated NSCLC.
The Role of HER2 Alterations in NSCLC
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Drs Allen and Socinski discussion the role of HER2 alterations in NSCLC and how it differs from breast cancer.
HER2 Alterations in NSCLC: Clinical Scenario
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Dr Solange Peters shares the molecular testing results for the patient in the presented clinical scenario.
Liquid vs Solid Tumor Biopsies in NSCLC
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Mark A. Socinski, MD, debates the merits of liquid versus tissue tumor biopsies in NSCLC biomarker testing.
Approaches to Biomarker Testing in NSCLC
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Timothy Craig Allen, MD, JD, FCAP, explains how he approaches biomarker testing in NSCLC and what testing he would have ordered in the presented scenario.
Biomarker Testing in NSCLC: Clinical Scenario
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS A panel of experts discusses the testing and targeting of HER2 in non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment selection.
Closing Expert Perspectives on Treatment in Advanced NSCLC
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Lung cancer experts share final thoughts on their thorough discussion of treatments in NSCLC and what to look for in the future.
Emerging Antibody Drug Conjugates in the Lung Cancer Treatment Landscape
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Dr Martin Dietrich gives an overview of novel antibody-drug conjugates in the NSCLC treatment landscape.
Recent Advances in Treatment of ROS1-Rearranged NSCLC
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Hatim Hussain, MD, explains emerging data on ROS1 rearrangements in NSCLC and his approach to treatment in his clinical practice.
Updates in Treatment of NSCLC with ALK Rearrangements
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Oncologists review data from the ALTA-1L clinical trial and CROWN study on therapies for the treatment of ALK rearrangements.
Treatment Selection and Sequencing for Patients with NTRK Fusions in Clinical Practice
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD A panel of lung cancer experts illustrate their personal clinical experience with treatment selection and sequencing for treating patients who have NTRK fusions.
Recent Advances in Treatment of NSCLC with NTRK Fusions
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Misako Nagasaka, MD, PhD, provides an overview of clinical trial data on treatments for NTRK fusion–positive lung cancer.
Treatment of KRAS G12C Mutant NSCLC
ByMisako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Benjamin Levy, MD,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Benjamin Levy, MD, explains KRAS G12C mutations in non–small cell lung cancer, and Hatim Husain, MD, provides insight into the mechanism of action of G12C inhibitors.
Recent Advances in Treatment of MET Exon 14 Skipping Mutations in NSCLC
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Dr Martin Dietrich provides an overview of how to treat MET exon 14 skipping mutations in non–small cell lung cancer.
Updates in Treatment of HER2 Mutant NSCLC
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Dr Misako Nagasaka reviews clinical trial data presented at ESMO 2021 on therapies for NSCLC harboring HER2 exon 20 mutations.
Recent Advances in Treatment of EGFR Exon 20 Insertion Mutations in NSCLC
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Dr Fernando Santini explains EGFR exon 20 insertion mutations in NSCLC and the best approaches for treating these cases.
Updates in Treatment of NSCLC with Classical EGFR Mutations
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD A discussion on EGFR mutations in non-small cell lung cancer and the combination treatment strategies for sensitizing mutations.
Challenges Associated with Molecular Testing in NSCLC
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD A look at the challenges associated with different molecular testing methods and the barriers that patients with non–small cell lung cancer face in getting tested.
Molecular Testing in NSCLC: What is the Optimal Sample and Time of Testing?
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD A panel of thought leaders describe the optimal sample to use in molecular testing in NSCLC and the appropriate time to perform testing in clinical practice.
Liquid Biopsies in the NSCLC Molecular Testing Algorithm
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Experts in lung cancer explain their views on the critical role of liquid biopsy in molecular testing in non–small cell lung cancer.
Testing Approaches for Actionable Mutations in NSCLC in Clinical Practice
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Oncologists provide insight into what actionable mutations they look for when they order molecular testing for patients with advanced non-small cell lung cancer.
Testing Approaches for Actionable Mutations in NSCLC in Clinical Practice